相似文献
1
Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?
Clin Infect Dis. 2020 Aug 14;71(4):1099-1101. doi: 10.1093/cid/ciz1159.
2
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155.
3
Aztreonam, Ceftazidime/Avibactam, and Colistin Combination for the Management of Carbapenemase-Producing Bacteremia: A Case Report.
J Pharm Pract. 2021 Aug;34(4):653-657. doi: 10.1177/0897190019882262. Epub 2019 Nov 7.
4
Synergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients.
Sci Rep. 2025 Feb 11;15(1):5102. doi: 10.1038/s41598-025-88965-7.
5
Past, present, and future perspectives on aztreonam and avibactam.
Expert Rev Anti Infect Ther. 2025 May;23(5):277-290. doi: 10.1080/14787210.2025.2473047. Epub 2025 Mar 4.
6
The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Lett Appl Microbiol. 2016 Aug;63(2):96-102. doi: 10.1111/lam.12592.
7
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
8
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
J Chemother. 2023 May;35(3):198-204. doi: 10.1080/1120009X.2022.2090615. Epub 2022 Jun 22.
9
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0052722. doi: 10.1128/aac.00527-22. Epub 2022 Aug 4.
10
Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.
Antimicrob Agents Chemother. 2011 Jan;55(1):390-4. doi: 10.1128/AAC.00756-10. Epub 2010 Nov 1.
引用本文的文献
1
Effects of different mechanisms on antimicrobial resistance in : a strategic system for evaluating antibiotics against gram-negative bacteria.
Microbiol Spectr. 2025 Apr;13(4):e0241824. doi: 10.1128/spectrum.02418-24. Epub 2025 Mar 5.
2
The impact of aztreonam-clavulanic acid exposure on gene expression and mutant selection using a multidrug-resistant .
Microbiol Spectr. 2025 Mar 4;13(3):e0178224. doi: 10.1128/spectrum.01782-24. Epub 2025 Feb 11.
3
The Tol Pal system integrates maintenance of the three layered cell envelope.
NPJ Antimicrob Resist. 2024 Dec 5;2(1):46. doi: 10.1038/s44259-024-00065-0.
4
Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens.
Pharmacotherapy. 2024 Dec;44(12):927-938. doi: 10.1002/phar.4629. Epub 2024 Nov 27.
5
Rapid Molecular Diagnostics of Pneumonia Caused by Gram-Negative Bacteria: A Clinician's Review.
Antibiotics (Basel). 2024 Aug 25;13(9):805. doi: 10.3390/antibiotics13090805.
6
The burden of antibiotic resistance of the main microorganisms causing infections in humans - review of the literature.
J Med Life. 2024 Mar;17(3):246-260. doi: 10.25122/jml-2023-0404.
7
Metabolomics unveil key pathways underlying the synergistic activities of aztreonam and avibactam against multidrug-resistant Escherichia coli.
Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1393-1405. doi: 10.1007/s10096-024-04837-4. Epub 2024 May 9.
8
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016-2020.
Antibiotics (Basel). 2023 Nov 3;12(11):1591. doi: 10.3390/antibiotics12111591.
9
Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study.
Infect Drug Resist. 2023 Sep 5;16:5815-5824. doi: 10.2147/IDR.S426326. eCollection 2023.
10
Endemic High-Risk Clone ST277 Is Related to the Spread of SPM-1-Producing during the COVID-19 Pandemic Period in Northern Brazil.
Microorganisms. 2023 Aug 11;11(8):2069. doi: 10.3390/microorganisms11082069.
本文引用的文献
1
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155.
2
Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01426-19. Epub 2019 Sep 30.
3
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Clin Infect Dis. 2020 Apr 15;70(9):1799-1808. doi: 10.1093/cid/ciz530.
4
Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
J Antimicrob Chemother. 2019 Jul 1;74(7):2051-2054. doi: 10.1093/jac/dkz125.
5
Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00010-19. Print 2019 May.
6
Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors.
Pharmacotherapy. 2019 Feb;39(2):182-195. doi: 10.1002/phar.2210. Epub 2019 Jan 20.
7
Successful Treatment of Bacteremia Due to NDM-1-Producing with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy.
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.02463-18. Print 2019 Feb.
8
Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016.
Diagn Microbiol Infect Dis. 2019 Mar;93(3):250-257. doi: 10.1016/j.diagmicrobio.2018.10.004. Epub 2018 Oct 13.
9
Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Surg Infect (Larchmt). 2019 Jan;20(1):55-61. doi: 10.1089/sur.2018.141. Epub 2018 Oct 23.
10
Transplant tourism complicated by life-threatening New Delhi metallo-β-lactamase-1 infection.
Am J Transplant. 2019 Apr;19(4):1224-1228. doi: 10.1111/ajt.15136. Epub 2018 Oct 29.
Zotero 插件